Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models

Francesco Strati 1*, Meritxell Pujolassos 2, Claudia Burrello 1, Maria Rita Giuffrè 1, Georgia Lattanzi 1, Flavio Caprioli 3,4, Jacopo Troisi 2,5† and Federica Facciotti 1†

Abstract

Background: The gut microbiota plays a central role in host physiology and in several pathological mechanisms in humans. Antibiotics compromise the composition and functions of the gut microbiota inducing long-lasting detrimental effects on the host. Recent studies suggest that the efficacy of different clinical therapies depends on the action of the gut microbiota. Here, we investigated how different antibiotic treatments affect the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in an experimental colitis model and in ex vivo experiments with human intestinal biopsies.

Results: Murine fecal donors were pre-treated with different antibiotics, i.e., vancomycin, streptomycin, and metronidazole before FMT administration to colitic animals. The analysis of the gut microbiome, fecal metabolome, and the immunophenotyping of colonic lamina propria immune cells revealed that antibiotic pre-treatment significantly influences the capability of the microbiota to control intestinal inflammation. Streptomycin and vancomycin-treated microbiota failed to control intestinal inflammation and were characterized by the blooming of pathobionts previously associated with IBD as well as with metabolites related to the presence of oxidative stress and metabolism of simple sugars. On the contrary, the metronidazole-treated microbiota retained its ability to control inflammation co-occurring with the enrichment of Lactobacillus and of innate immune responses involving iNKT cells. Furthermore, ex vivo cultures of human intestinal lamina propria mononuclear cells and iNKT cell clones from IBD patients with vancomycin pre-treated sterile fecal water showed a Th1/Th17 skewing in CD4+ T-cell populations; metronidazole, on the other hand, induced the polarization of iNKT cells toward the production of IL10.

(Continued on next page)
Conclusions: Diverse antibiotic regimens affect the ability of the gut microbiota to control intestinal inflammation in experimental colitis by altering the microbial community structure and microbiota-derived metabolites.

Keywords: FMT, IBD, Antibiotics, Gut microbiota, iNKT

Background
The human gut microbiota plays a crucial role in maintaining the integrity of the GI tract, the immune system homeostasis, and the host energy metabolism. Alterations of this network can lead to pathological abnormalities and inflammation [1]. Antibiotics revolutionized medicine regarding the treatment of infectious diseases worldwide; however, their effects are not limited to pathogens for which they are prescribed and indiscriminately affect also the growth of beneficial microbes, including those residing in the gut [2]. By decreasing the diversity of the microbiota, antibiotics compromise host-microbes interactions, immune system homeostasis [2], and impair colonization resistance toward incoming pathogenic bacteria [3]. Indeed, antibiotic treatments worsen the severity of dextran sodium sulfate (DSS)-induced colitis, a mouse model of inflammatory bowel diseases (IBD), through the disturbance of toll-like receptors (TLRs) signaling [4]. Antibiotic-induced dysbiosis promote also sustained T cell-mediated dysfunctions and increased susceptibility to inflammation and infections by interfering with microbiota-dependent regulation of intestinal innate immunity [5]. Accordingly, we showed that short-term broad-spectrum oral antibiotic treatment profoundly affects the phenotype and function of mucosal immune cell populations by inducing inflammatory activation of colonic iNKT and T helper cells [6]. These studies highlight the important implications of repeated broad-spectrum antibiotic use and the breakdown of tolerance mechanisms between the microbiota and the immune system. Strong epidemiological evidences link antibiotic usage early in life with an increased risk of inflammatory conditions such as IBD, indicating an important role for the gut microbiota in modulating intestinal immunity [7, 8]. It has been proposed that the effects of antibiotics on gut microbiota composition and host physiology may relate to their mechanism of action. For instance, vancomycin, which is a Gram+ targeting drug [9] affects also Gram− commensals causing lasting susceptibility to a variety of secondary infections [10]. On the contrary, low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn’s disease after ileal resection [11].

Presently, little is known about the interaction between the gut microbiota, their metabolites, and relevant inflammatory responses in the gut and the impact on host immunity. We recently showed that control of experimental intestinal inflammation by fecal microbiota transplantation (FMT) is dependent on the transfer of a core microbial ecology composed by different bacterial taxa (Bacteroidales S24-7, Lachnospiraceae, Lactobacillaceae, Ruminococcaceae, Rikenellaceae, Bifidobacteriaceae, and Erysipelotrichaceae) sharing similar metabolic functions (i.e., SCFA production, pH control, free radicals scavenging) [12, 13]. We showed that when this core microbiota is maintained at a certain population level, it creates environmental conditions sufficient to inhibit the growth of pathogenic species/pathobionts, shapes host mucosal immune cell functions, and supports optimal host health [13]. Indeed, transfer of a gut microbiota enriched in these bacterial taxa during acute and chronic experimental colitis is capable to modulate directly both innate and adaptive mucosal immune responses by inducing IL10-dependent anti-inflammatory responses [12, 13].

Here, we investigated how antibiotics-conditioned gut microbiota modulates the disease outcome in a model of experimental colitis upon FMT. Amplicon-based 16S rRNA gene analysis of the gut microbiota, fecal metabolomics, and immunophenotyping of colonic lamina propria (LP) immune cells in recipient colitic animals were analyzed. Reciprocal functional interactions between the microbiota, the metabolome, and the mucosal immune system were analyzed to identify key elements fundamental for the restoration of a healthy gut microenvironment and the re-instruction of the immune system toward homeostasis. In vitro/ex vivo experiments in human settings further confirmed our findings.

Taken together, our results shed lights on the effects that alteration of the gut microbiota composition, e.g., by antibiotic treatment, may have on the gut microbiota and its capacity to induce or control intestinal inflammation. These findings may be of pivotal importance in those therapeutic settings in which restoration of homeostatic host-microbes interactions and immune functions are required for the stable management of inflammatory disease.

Methods
Mice
C57BL/6 mice (Charles River, IT) of 8-10 weeks of age were housed at the IEO animal facility in SPF conditions. Experimental groups of mice receiving FMT treatments were kept in separate cages. Littermates of the same sex and age were randomly assigned to the
different experimental groups. Animal experimentations were approved by the Italian Ministry of Health (Auth. 415/2017) and by the animal welfare committee (OPBA) of the European Institute of Oncology (IEO), Italy.

**Experimental colitis model and FMT treatments**

For the induction of DSS-mediated acute colitis, mice were given 2% (w/v) dextran sodium sulfate (DSS, MW 40 kDa; TdB Consultancy) in their drinking water for 7 days followed by 2 days of recovery. At sacrifice, colons were collected, their length was measured and divided in portions to isolate lamina propria mononuclear cells (LPMC). FMT was performed through oral gavage of mucus (first day) and feces (second and third days) preparations from donor mice as previously described [13]. Microbiota for FMT was obtained from untreated (nornobic) mice or mice treated with metronidazole (1 g/L), vancomycin (1 g/L), or streptomycin (2 g/L). Mucus was scraped from colons, diluted in PBS, and administered to recipients at 1:1 ratio. Feces were collected, diluted in PBS (50 mg/ml), and administered to recipients by oral gavage (10 mg/mouse) 1 day after the end of acute DSS administration to recipient animals.

**Inflammation immunoscore**

Clinical (colon length) and immunological (proinflammatory genes expression, CD4+T colonic infiltrate and IL10 protein level) parameters were evaluated in colitic mice undergoing or not FMT treatment. A scoring system has been generated and used to evaluate the inflammation status of mice in 5 independent experiments. Points were recorded according to the following scale: Colon length, > 7 cm (0), 6-6.9 cm (1), < 5.9 cm (2); proinflammatory gene expression (Hbb and Tnf), < 0.0099 (0), 0.01-0.099 (1), > 0.099 (2); CD4+T cell infiltrate (abs numbers and % ki67+), < 5000 and < 10% (0), 5000-15000 and 10-20% (1), > 15000 and > 20% (2); IL10 protein expression (pg), > 20000 (0), 10000-20000 (1), < 10000 (2).

**Murine cell isolation**

Single-cell suspensions were prepared from the colon of C57BL/6 mice as previously described [13]. LPCMs were isolated from colons upon incubation with 5 mM EDTA at 37 °C for 30 min, followed by further digestion with collagenase IV and DNase at 37 °C for 1 h. Cells were then separated with a Percoll gradient. After isolation, some cells were re-stimulated in vitro for 3 h with PMA/ ionomycin in the presence of Brefeldin A for cytokine secretion.

**RT-qPCR of tissue mRNA**

Total RNA from colonic tissues was isolated as previously described [13]. cDNAs were generated from 1 μg of total RNA with reverse transcription kit (Promega). Gene expression levels were evaluated by qPCR and normalized to Rpl32 gene expression.

**16S rRNA gene sequencing and data analysis**

DNA extraction, 16S rRNA gene amplification, purification, library preparation, and pair-end sequencing on the Illumina MiSeq platform were performed as described in [13]. Reads were pre-processed using the MICCA pipeline (v.1.5) (http://www.micca.org) [14]. Forward and reverse primers trimming and quality filtering were performed using `micca trim` and `micca filter`, respectively. De novo greedy clustering and chimera filtering were performed by using `micca otu`: operational taxonomic units (OTUs) were assigned by clustering the sequences with a threshold of 97% pairwise identity, and their representative sequences were taxonomically classified using `micca classify` with the RDP classifier [15]. Multiple sequence alignment (MSA) of 16S rRNA gene sequences was performed using the Nearest Alignment Space Termination (NAST) [16] algorithm implemented in `micca msa` with the template alignment clustered at 97% similarity of the Greengenes database [17] (release 13_05). Phylogenetic trees were inferred using `micca tree` [18]. Sampling heterogeneity was reduced rarefying samples at the depth of the less abundant sample using `micca table rare`. Alpha (within-sample richness) and beta-diversity (between-sample dissimilarity) estimates were computed using the phyloseq R package [19]. Permutational multivariate analysis of variance (PERMANOVA) test was performed using the adonis() function in the R package vegan with 999 permutations. Linear discriminant effect size analysis (LEfSe) was performed to find features (microbial taxa) most likely to explain differences between classes [20]. Random Forest [21] analyses of 16S rRNA gene sequencing data were performed using the randomForest R package; permutation tests with 1000 permutations were performed to assess model significance [22].

**Metabolomic analysis**

Metabolome extraction, purification, and derivatization were carried by means of the MetaboPrep kit (Theoreo srl, Montecorvino Pugliano, Salerno, Italy) according to the manufacturer’s instruction. Two-microliter samples of the derivatized solution were injected into the GC-MS system (GC-2010 Plus gas chromatograph coupled to a 2010 Plus single quadrupole mass spectrometer; Shimadzu Corp., Kyoto, Japan). Chromatographic separation was achieved as previously reported [13, 23] using a 30 m 0.25 mm CP-Sil 8 CB fused silica capillary GC column with 1.00 μm film thickness from Agilent (Agilent, J&W Scientific, Folsom, CA, USA), with helium as carrier gas. Untargeted metabolites were identified by
were then separated with a Percoll gradient and cultured in complete RPMI 1640 medium containing 5% human serum (Sigma-Aldrich) and 100 U/ml IL-2 (Proleukin). LPMCs were plated at a density of $2 \times 10^5$ and treated with the fecal water samples (1:5 v/v, fecal water:cells) for 24 h. At the end of the experiment, cells were analyzed with flow cytometry and supernatants were collected for ELISA assays. Cell viability was checked with Zombie Yellow™ Fixable Viability Kit (Biolegend).

**iNKT cell clones generation and in vitro stimulation**

Human iNKT cell lines were generated from sorted CD45$^+$CD3$^+$CD1d:PBS57Tet$^+$ cells isolated from total LPMCs as previously described [28]. Sorted iNKT cells were expanded in vitro for 2 weeks in the presence of irradiated peripheral blood feeders, hIL2 (100 U/ml; Proleukin), and PHA (1 μg/ml; Sigma-Aldrich). iNKT cell clones were generated via cloning by limiting dilution according to the protocol described in [29]. For fecal water stimulation, $5 \times 10^4$ THP1 cells were plated in each well in 1:1 ratio with human iNKT cells and treated with the fecal water samples (1:5 v/v, fecal water:cells) for 24 h. αGalCer was used at 100 ng/ml as control for iNKT cells stimulation.

**Flow cytometry**

Human and murine LPMCs were stained with labeled antibodies diluted in PBS with 1% heat-inactivated fetal bovine serum (FBS) for 20 min on ice. Intracellular staining of cytokines was performed after cell fixation and permeabilization with cytovix/cytoperm (BD) before addition of the antibodies. Samples were analyzed with a FACSCelesta flow cytometer (BD Biosciences, Franklin Lakes NJ, USA). The antibodies and dyes used in the study are reported in Table S1. Data were analyzed using the FlowJo software (TreeStar, Ashland, OR, USA) or FACS Diva software (BD Biosciences, Franklin Lakes NJ, USA).

**ELISA assay**

Cytokines from LPMC supernatants were detected by coating with anti-human capturing antibody for IL17, IFNγ, TNFα, IL6, and IL10 (Biolegend) overnight at 4°C. Blocking of the plates was performed with PBS/BSA 1% for 1 h at room temperature, while sample incubation was performed overnight at 4°C. Standards and samples were analyzed in duplicates. Protein detection was performed with 1 μg/ml of biotin anti-human detection antibody for IL17, IFNγ, TNFα, IL6, or IL10 (Biolegend) for 2 h at room temperature. Streptavidin-HRP conjugate (Biolegend) and TMB chromogen solution (ThermoFisher) were used to develop the assay, according to manufacturer’s instruction. Reaction was blocked using sulfuric acid 1 N. Plates were read at a wavelength of 450 nm. Murine colonic tissues were homogenized in
Fig. 1 (See legend on next page.)
300 μl RIPA buffer (Cell Signaling Technology) supplemented with phosphatase inhibitors (Sigma) and protease inhibitors (Complete Ultra tablets, Roche). The samples were then incubated at 4°C for 30 min under slow rotation and then centrifuged at 13000 rpm for 15 min at 4°C. The supernatant was quantified at the NanoDrop with Bradford Assay (BioRad). mIL10 was measured on 6.25 μg of lysate using an ELISA assay (Purified anti-mouse IL10 and Biotin anti-mouse IL10, Biolegend) performed following manufacturer’s instructions.

**Statistical analysis**

Statistical analyses were performed using R [30] and GraphPad Prism v8.3.1 (GraphPad Software, La Jolla, CA, USA). At least two independent replicates have been performed per each experiment. Data were represented as boxplot, i.e., with the lower and upper hinges corresponding to the first and third quartiles (the 25th and 75th percentiles). The upper and lower whiskers extend no further than ± 1.5xIQR from the hinges. Outliers were plotted individually. Otherwise, data were represented as barplot with mean ± standard error of the mean (SEM). The Wilcoxon rank-sum test was used for the comparison between groups, and the resulting p values were corrected for multiple testing controlling the false discovery rate (FDR) [31] if not stated otherwise. Spearman’s correlation tests were computed using the `psych` R package [32] and p values were FDR-corrected [31] for multiple comparisons. No data were excluded from analyses.

**Results**

**Antibiotics pre-conditioning affects the ability of the gut microbiota to control intestinal inflammation upon FMT**

The composition of the gut microbiota transferred into colitic recipients influence FMT success rate [33]. To understand the impact of gut microbiota alterations on inflammatory conditions, wild-type SPF murine stool donors were pre-treated with antibiotics having different mechanisms of action, i.e., metronidazole, streptomycin, and vancomycin, before FMT administration to recipient colitic animals. The effect of the treatment on disease outcome was evaluated by using a scoring system accounting for clinical and immunological parameters (see the “Methods” section). Pre-conditioned metronidazole FMT-treated mice (DSS + Metronidazole mice) showed reduced signs of intestinal inflammation similar to mice treated with normobiotic fecal samples (DSS FMT mice), as indicated by decreased inflammation score and increased colon length compared to untreated colitic mice (DSS mice) (Fig. 1a). On the contrary, pre-conditioned streptomycin and vancomycin FMT-treated mice (DSS + Streptomycin and DSS FMT + Vancomycin mice, respectively) showed clear signs of intestinal inflammation, similar to those observed in DSS mice (Fig. 1a). Notably, half of DSS FMT + Vancomycin animals in the study were sacrificed before the experimental endpoint because of colitis severity. To track the modifications of the gut microbiota induced by the different antibiotic treatments upon FMT in colitic animals, we performed a metataxonomic analysis of FMT recipients. The microbiotal community structures among groups were significantly different as measured by beta-diversity of Bray-Curtis dissimilarity, (PERMANOVA p < 0.05; Fig. 1b; Table S2) suggesting diverse microbial engraftments after FMT. The relative abundances of various taxa were different among groups (Fig. 1c). We observed higher levels of Akkermansia, unclassified Bacteroidetes, Alitipes, Bifidobacterium, and Clostridia (i.e., Clostridium XI, Clostridiales uncl.) in DSS FMT mice. DSS FMT + Streptomycin and DSS FMT + Vancomycin animals showed the enrichment of the genera Bacteroides, Parabacteroides, Streptococcus as well as the reduction of other taxa among which Bifidobacterium, Mucispirillum, unclassified Clostridiales1, and Clostridium XI. Noteworthy, DSS FMT + Metronidazole mice, that retained a full capability to control intestinal inflammation compared to DSS FMT + Streptomycin and DSS FMT + Vancomycin animals, showed a significant increase of the genus Lactobacillus (Fig. 1d). The gut microbiota was able to predict samples according to treatment among untreated colitic mice, normobiotic FMT-treated, and antibiotic pre-conditioned FMT-treated animals by using a Random Forest classifier. The most important features selected by the classifier were indeed among those differentially abundant among groups (Fig. 1d, e). With an out-of-bag (OOB)
Fig. 2 (See legend on next page.)
error rate of 29.5%, the classifier showed a moderate but significant prediction power (permutation tests p value = 0, accuracy = 69%, kappa = 43%). The classification error was 0.8% for DSS FMT and 90% for DSS samples. These data collectively suggests that FMT is important to stabilize the gut microbiota during experimental colitis despite the inflammatory status of the host.

Transfer of antibiotics pre-conditioned microbiota in DSS colitic recipients influences colonic iNKT and CD4$^+$ T cell populations

The gut microbiota has a profound effect on the intestinal immune system functionality [1]. Therapeutic FMT administered during experimental colitis directly modulates mucosal immunity promoting IL10-dependent anti-inflammatory responses [12, 13].

Thus, we analyzed the colonic immune cell landscape of FMT-treated animals in relation to the gut microbiota composition (Fig. 2). The presence/absence of specific bacterial taxa in the gut has been linked to the differentiation and expansion of conventional [34] and unconventional CD4$^+$ T cells [35]. Accordingly, we observed an increase in the numbers of total and proliferating iNKT and CD4$^+$ T cells in control colitic animals and FMT recipients treated with a gut microbiota altered by antibiotics preconditioning (Fig. 2a). In particular, DSS mice showed a significant enrichment of CD4$^+$ and CD4$^+$Ki67$^+$ T cells compared to normobiotic FMT-treated animals. On the other hand, antibiotic preconditioning of the gut microbiota induced the significant increase of LP iNKT cells (Fig. 2b). These data suggest that different members of the gut microbiota modulate the abundance of pro- and anti-inflammatory immune cell populations dictating the success of FMT treatments to control inflammation.

Antibiotics treatments shape the gut microenvironment and microbiota-derived metabolites of DSS colitic recipients

The phylogenetic composition of the gut microbiota is much more dynamic than community metabolism, as a consequence of microbial functional redundancy [36]. Given the relevant biological implications for host-microbiome interactions, in order to identify microbiota-derived metabolites important to modulate intestinal inflammation, we performed an untargeted metabolomics analysis of fecal samples in colitic animals upon FMT (Fig. 3). We observed significantly different metabolic profiles among groups (Fig. 3a) with azelaic acid, maltose, gluconic acid, norvaline, and erythrose being the metabolites with the highest discriminatory power (Fig. 3b). Higher levels of azelaic and gluconic acids were detected in DSS FMT + Vancomycin mice as well as of erythrose in DSS FMT + Streptomycin mice (Fig. 3c). The gut metabolome was also able to cluster samples according to their inflammation status (i.e., inflamed vs non-inflamed independently by the treatment) (Figure S1a and b) while the gut microbiota failed to do so (Figure S1c). Nevertheless, we have been able to identify bacterial taxa usually associated with inflammatory conditions and IBD, e.g., Escherichia/Shigella and Fuso-bacterium in inflamed vs non-inflamed samples (Figure S1d).

We then correlated metabolomics and gut microbiota data observing the significant correlation of ferulic acid, gluconate, lactose, and norvaline with different bacterial taxa among which Akkermansia, Bacteroidetes uncl., Clostridium XVIII, Escherichia/Shigella, and Lactobacillus (Fig. 3d). These data suggest that the transfer of different configurations of the gut microbiota affected by antibiotics enrich the gut microenvironment with metabolites that may dictate the status of intestinal inflammation.

Exposure to a vancomycin-conditioned gut microenvironment skew human CD4$^+$ T cells population toward a Th1/Th17 phenotype while metronidazole promotes IL10 secretion by iNKT cells

Based on our previous data, we hypothesized that the metabolic products of gut microbiota may have an
Fig. 3 (See legend on next page.)
important role on the polarization of the host’s immune responses to modulate inflammation. Therefore, we performed an ex vivo experiment in which we exposed human colonic lamina propria mononuclear cells (LPMC) of ulcerative colitis patients to sterile fecal water (FW) from antibiotic pre-conditioned human healthy fecal microbiota to mimic the colonic microenvironment of our in vivo model (Fig. 4a). According to our hypothesis, we observed the skewing of CD4+ T cells toward a Th1/Th17 phenotype in the LPMC exposed to the FW from vancomycin-treated microbiota (Fig. 4c and d) as well as significantly higher levels of TNF production compared to metronidazole and untreated (antibiotic-free) FW. TNF levels were significantly increased also upon exposure to streptomycin FW (Fig. 4e). To note, monocytes and APC were not affected by FW treatments. Since iNKT cells were significantly affected by the antibiotics-conditioned microbiota in our in vivo colitis model, we performed an in vitro assay by exposing human intestinal iNKT cell clones isolated from IBD patients [28] to FW. We observed the polarization of iNKT cells toward the production of IL10 upon exposure to the metronidazole-conditioned FW as well as from the untreated FW (Fig. 4b). Interestingly, the microbial composition of the human fecal microbiota after antibiotic exposure (Figure 5a) showed few differences involving principally the genera Bacteroides, Lachnospiraceae incertae sedis, Dorea, Oscillibacter, and Peptostreptococcaceae (Fig. 5b). The metabolomic analysis of the FW samples on the contrary showed distinct metabolic profiles according to the type of antibiotic treatment (Figure 5c) with some highly discriminant metabolites deriving from amino acid catabolism, e.g., glutaric acid, succinate, amino malonate, and urea (Fig. 5d, e). Notably, we observed the significant enrichment of butyric acid in the streptomycin-conditioned FW (Fig. 5f, g), a possible indication for reactive oxygen species (ROS) production and accumulation of 8-oxoG lesions [37–39] despite the role of butyrate in regulating homeostatic immune responses [40, 41].

Discussion

Breakdown of the complex interplay between the host immune system and the microbiota increases the risk of pathogen infection, the overgrowth of harmful pathobionts, and inflammatory disease. Although remarkable results have been obtained in understanding the role of the gut microbiota in different human pathologies and on the efficacy of therapies such as FMT and cancer immunotherapy [42, 43], there is paucity of data regarding the mechanism of action for the control of inflammation and the role that different commensals may have on intestinal immune responses. Here, we investigated how modifications of the gut microbiota by different antibiotic treatments affect the disease outcome in a model of acute experimental colitis upon FMT. We further expanded our results paralleling the findings observed in the animal model in a human setting by using colon biopsies from ulcerative colitis patients. We demonstrate that the transfer of an antibiotic-conditioned gut microbiota in colitic animals has an important role for the disease outcome and for the modulation of the inflammatory status, achieved by polarizing the immune response of the FMT recipient and modifying the gut microenvironment. In particular, the colitic recipients transferred with a streptomycin- or vancomycin-conditioned microbiota were characterized by blooming of the genera Bacteroides, Parabacteroides, Streptococcus, and unclassified Enterobacteriaceae, all associated with poor outcomes in human clinical studies evaluating FMT efficacy in IBD patients [44–46] as well as by the depletion of health-promoting bacteria, i.e., Akkermansia and Bifidobacterium [47, 48]. The gut microenvironment associated with these dysbiotic microbial communities showed the specific enrichment of metabolites that are abundant in the mouse gut after antibiotic treatments leading to susceptibility to Clostridiodes difficile infections, i.e., gluconic acid [49], or during steatohepatitis, i.e., azelaic acid [50]. The immunological landscape of the recipients transferred with a vancomycin- or streptomycin-conditioned microbiota showed an increased infiltration of proinflammatory polymorphonuclear leukocytes and monocytes as well as proliferating iNKT cells in the intestinal LP. Since colonic APC levels and Ki67+iNKT cells have been shown to contribute to IBD pathogenesis [6, 13, 28, 51, 52], this could explain the inability of these microbiota configurations to control inflammation. Several reports described also the pivotal role of T cells as key
Fig. 4 Ex vivo LPMC and iNKT cells stimulation assay with sterile filtered fecal water from antibiotic pre-conditioned human healthy donor's microbiota. a Schematic representation of the experiment. b Frequencies of IL10 producing iNKT cells upon exposure to sterile fecal water from antibiotic pre-conditioned healthy donor's microbiota. *p < 0.05, **p < 0.01, Mann-Whitney U test. c Representative contour plots. d Frequencies of IFNγ and IL17 secreting CD4+ T-cells from UC LPMC upon exposure to sterile fecal water from antibiotic pre-conditioned healthy donor's microbiota. *p < 0.05, **p < 0.01, unpaired t test. One representative experiment out of at least two is shown.
Fig. 5 (See legend on next page.)
players in the initiation and maintenance of intestinal inflammation through the recognition of bacterial antigens in IBDs [1]. Accordingly, exposure of LPMC from ulcerative colitis patients to vancomycin- and streptomycin-conditioned gut microenvironments (i.e., sterile fecal water) enriched with microbiota-derived metabolites polarized T cells toward a proinflammatory Th1/Th17 phenotype and the production of mediators of systemic inflammation, i.e., TNF. This effect could be mediated by the antibiotic-induced alteration of bacterial metabolism, since short-term exposure of healthy human microbiota to antibiotics caused alterations of amino acid catabolic products and enrichment of butyric acid. Although microbiota-derived butyrate is an important mediator of intestinal immune homeostasis [40, 41], other studies suggest that the gut microbiota, partially through an altered production of butyrate, induces ROS and the accumulation of 8-oxoG lesions, therefore contributing to inflammation and tumorigenesis [37–39]. On the other hand, the recipients that received FMT with a metronidazole-conditioned microbiota were able to control inflammation by reducing colitis severity. We hypothesize that this effect may be in part mediated by the genus Lactobacillus. Indeed, lactobacilli have a long history of use as health-promoting bacteria and several studies supported their role in the maintenance of intestinal homeostasis [53, 54]. The recipients receiving the metronidazole-conditioned microbiota showed the enrichment of cellobiose, a metabolite boosting the intestinal levels of Lactobacillus and Bifidobacterium [55]. Nevertheless, cellobiose is also used as a marker of intestinal permeability in Crohn’s disease patients [56]. Lactobacillus and Bifidobacterium promotes the release of anti-inflammatory IL10 by APC and T cells, which is pivotal for the resolution of intestinal inflammation [57] by reducing the proliferative capacity of proinflammatory T cells [13]. Also, iNKT cells produce IL10 in murine models of inflammatory disease upon therapeutic FMT [13]. Accordingly, the exposure of human-isolated iNKT cell clones to metronidazole-conditioned fecal water promoted the secretion of IL10, supporting the hypothesis that metronidazole shapes the microbiota and the gut microenvironment favoring a better control of colitis severity and inflammation compared to streptomycin and vancomycin.

Conclusions
Taken together, our findings confirm that the ability of the gut microbiota to control inflammation is in part mediated by the production of microbiota-derived metabolites. Alterations of the gut microbiota induced by different antibiotic treatments, such as with vancomycin and streptomycin, polarize the immune system toward a pro-inflammatory configuration abating any benefits of FMT. Metronidazole treatment, on the contrary, allowed the retention of a beneficial microbiota that reduced the severity of colitis suggesting that not all antibiotic treatments are associated with generalized detrimental effects on host-microbes interactions.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s40168-020-00991-x.

Additional file 1: Figure S1. Gut Microbiota composition and metabolomics analysis of the antibiotics-conditioned human fecal samples used for the ex vivo experiments. a Mean relative abundance at genus level of the antibiotics-conditioned human gut microbiota. All genera with relative abundance < 0.5% are reported together and labeled as “others.” b Significantly different taxa identified in the antibiotics-conditioned human gut microbiota. Exact p values are shown; unpaired t test. c Partial least square discriminant analysis showing clustered fecal water samples according to the type of antibiotic treatment. d Metabolites that differentiate samples according to treatment by variable important in projection (VIP) scores. e Normalized concentrations of metabolites with the highest discriminative power (VIP score > 1.5) for the classification of samples according to the type of treatment. f One-way analysis of variance; red dots indicate the significant metabolites (p < 0.05) after FDR-correction. g Normalized concentration of butyric acid as measured in FW samples. *p < 0.05, **p < 0.01, *** < 0.001; unpaired t test

Additional file 2: Table S1. FACS antibodies and dyes.

Additional file 3: Table S2. PERMANOVA of beta-diversity analysis as measured by Bray-Curtis dissimilarity.

Additional file 4: Table S3. Sample metadata, unrarefied OTU table and taxonomic classifications.

Abbreviations
ABX: Antibiotics; APC: Antigen-presenting cells; DSS: Dextran sodium sulfate; FMT: Fecal microbiota transplantation; IBD: Inflammatory bowel diseases; LP: Lamina propria; LPMC: Lamina propria mononuclear cells; Th: T-helper

Acknowledgements
We would like to thank Erika Miletic and Angelica Diaz-Basabe (IEO) for assistance during the study, the IEO animal facility for the excellent animal husbandry, and Marta Stefanucci (Ospedale Maggiore Policlinico) for the help in collecting human specimens.

Authors’ contributions
CB, FS, JT, and FF designed the experiments. MP, MRG, GL, CB, and FS performed the experiments. JT and FS analyzed the data. FC recruited subjects and provided reagents. FS wrote the manuscript. FF conceived the
study and revised the manuscript. All the authors critically reviewed and approved the manuscript.

**Funding**

This work was financially supported by the Italian Ministry of Health (IRCCS, Bari; PRIN 2016-02361174) and by ARC-Investigator Grant 2019 22923 to FF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Availability of data and materials**

16S rRNA gene sequencing raw data are available in SRA Repository with accession number PRJNA446880 and in the European Nucleotide Archive with accession number PRJEB41434. Sample metadata, un rar eferred OTU table, and taxonomic classification are available in the Supplementary Table S3.

**Ethics approval and consent to participate**

Animal experimentations were approved by Italy’s Ministry of Health (Auth. 415/2017) and by the animal welfare committee (OPBA) of the European Institute of Oncology (IEO), Italy. The human study was approved by the ethics committee (Comitato Etico Milano Area 2) of the Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy; and by the ethics committee of the University of Trieste (Comitato Etico Università di Trieste) 2016, Italy.

**Competing interests**

The authors declare no competing interests.

**Author details**

1. Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy. 2Theoreo srl, Spin-off Company of the University of Trieste and University of Treviso, Trieste, Italy. 3Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. 4Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy. 5European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.

Received: 4 August 2020 Accepted: 29 December 2020

Published online: 06 February 2021

**References**

1. Kamada N, Sato S, Chiba Y, Nunez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–35.
2. Modi SR, Collins JJ, Reisman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124(10):4212–8.
3. Baumlter AJ, Sperandio V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 2016;535(7610):85–93.
4. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–40.
5. Scott NA, Andrusaite A, Andersen P, Lawson M, Alcon-Giner C, Leclaire C, et al. A flora-specific toll-like receptor triggers pathogenic mechanisms in IBD-derived intestinal iNKT cells. Life Sci Alliance. 2018;1:521.
6. Scott NA, Andrusaite A, Andersen P, Lawson M, Alcon-Giner C, Leclaire C, et al. Depletion of TLR7/8/9 mediates anti-inflammatory activity of FDRQ-04. J Immunol. 2017;199(6):2229–31.
7. Korman MP, Zaouitsis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130(6):e1794–803.
8. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Ann J Gastroenterol. 2010;105(12):2687–92.
9. Ulbeda C, Taur Y, Jenq RR, Equinda MJ, Song T, Samstein M, Vale A, Socci ND, van den Brink MR, Kamboj M, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120(12):4322–32.
10. Lewis BB, Buffie CG, Carter RA, Leiner I, Toussaint NC, Miller LC, Gobourne A, Ling L, Palmer EG. Loss of microbiota-mediated colonization resistance to clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis. 2015;212(10):1656–65.
11. Glick LR, Sossehmer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT. Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn’s disease after ileal resection: a retrospective cohort study. J Crohns Colitis. 2019;13(9):1158–62.
12. Burrello C, Giuffre MF, Macandog AD, Diaz-Basabe A, Criibiu FM, Lopez G, Borgo F, Nezi L, Caprioli F, Vecchi M, et al. Fecal microbiota transplantation controls murine chronic intestinal inflammation by modulating immune cell functions and gut microbiota composition. Cells. 2019;8(6):517.
13. Burrello C, Garavaglia F, Cribiu FM, Ercoli G, Lopez G, Troisi J, Colucci A, Guglietta S, Carfoni S, Guglielmetti S, et al. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat Commun. 2018;9(1):15194.
14. Albanese D, Fontana P, De Filippo C, Cavalletti D, Donati C, MCCA: a complete and accurate software for taxonomic profiling of metagenomic data. Sci Rep. 2015;5:9743.
15. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261–73.
16. DeSantis T, Hugenholtz P, Keller K, Brodie E, Larsen N, Piceno Y, Beford S, Medzhitov R. NAST: a multiple sequence alignment server for comparative analysis of 16S rRNA genes. Nucleic Acids Res. 2006;34(suppl 2):W394–9.
17. DeSantis T, Hugenholtz P, Larsen N, Rojas M, Keller K, Huber T, Dalevi D, Hu P, Andersen GL. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72(7):4676–9.
18. Price MN, Dehal PS, Arkin AP. FastTree 2—a maximum-likelihood trees for large alignments. PLoS One. 2010;5(3):e9490.
19. McMurdie PJ, Holmes S. Phyloseq: an R package for reproducible interactive interactive analysis and graphics of microbiome census data. PLoS One. 2013;8(4):e61217.
20. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.
21. Breilman L. Random Forests. Machine Learning. 2001;45(1):5–32.
22. Murphy MA, Evans JS, Sterfo A. Quantifying buoy bores connectivity in Yellowstone National Park with landscape genetics. Ecology. 2010;91(1):252–61.
23. Roggero P, Liocono N, Pozzi C, Braga G, Troisi J, Menis C, Gianni ML, Berni Canani R, Paparo L, Nocentini R, et al. Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula. Nat Commun. 2020;11(1):2703.
24. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW, Fiehn O, Goodacre R, Griffin JL, et al. Proposed minimal reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 2007;3(3):21–21.
25. Wold S, Sjostrom M, Eriksson L. PLS-regression: a basic tool of chemometrics. PLS Methods. 2001;58:109–30.
26. Synti-Aho M, Katajamaa M, Yetukuri L, Oresic M. Normalization method for metabolomics data using optimal selection of multiple internal standards. BMC bioinformatics. 2007;8:93.
27. Capotilli F, Pallone F, Monteleone G. Th17 immune response in IBD: A new pathogenic mechanism. J Crohns Colitis. 2008;2(4):291–9.
28. Burrello C, Pellegrino G, Giuffre MF, Lovati G, Magagnola I, Bertocchi A, Criibiu FM, Boffgio F, Botti F, Trombetta E, et al. Utilization of metabolomics for identifying pathogenic mechanism in IBD-derived intestinal iNKT cells. Life Sci Alliance. 2019;2(1):e201800229.
29. Mariotti S, Nisini R. Generation of human T cell clones. In: T Cell Protocols. edn.: Springer; 2009. 65–93.
30. Team RC: A language and environment for statistical computing. R Foundation for statistical computing. R Foundation for statistical computing. 2015; Vienna, Austria. In; 2016.
31. Benjamin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995: 289–300.
32. Reveille J, Psych: procedures for psychological, psychometric, and personality research. R package version 1.3. 10. Evanston: Northwestern University; 2013.
33. Kump P, Wurm P, Grochenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther. 2018;47(1):57–77.
34. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karioz U, Wei D, Goldfarb KC, Santee CA, Lynch SW. Induction of intestinal TH17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485–98.

35. An D, Oh SF, Olszak T, Neves JF, Avci FY, Enrik-Hademir D, Lu X, Zeissig S, Blumberg RS, Kasper DL. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell. 2014;156(1-2):123–33.

36. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14.

37. Irizubia T, Thakur BK, Kang M, Malaise Y, Streutker C, Wong EOY, Copeland J, Gryfe R, Guckman DS, Navaree WW, et al. Limiting oxidative DNA damage reduces microbe-induced colitis-associated colorectal cancer. Nat Commun. 2020;11(1):1802.

38. Belcheva A, Irizubia T, Robertson SJ, Streutker C, Maughan H, Hucino S, Moriyama EH, Copeland JK, Surendra A, Kumar S, et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell. 2014;158(2):288–99.

39. Kumar A, Wu H, Collier-Hyams LS, Kwon YM, Hanson JM, Neish AS. The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol. 2009;182(1):538–46.

40. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN, Garett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73.

41. Furusawa Y, Obata Y, Fukuda S, Nakanishi K, Takahashi D, Endo TA, Nakato G, Takahashi K, Kato T, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013; 504(7482):446–50.

42. Amoroso C, Perillo F, Strati F, Fantini M, Caprioli F, Facciotti F. The role of gut microbiota biomarkers on mucosal immunity and intestinal inflammation. Cells. 2020;9(5):1234.

43. Perillo F, Amoroso C, Strati F, Guiffre MR, Diaz-Basabe A, Lattanzi G, Facciotti F. Gut microbiota manipulation as a tool for colorectal cancer management: recent advances in its use for therapeutic purposes. Int J Mol Sci. 2020; 21(15):5389.

44. Gao X, Cao Q, Cheng Y, Zhao D, Wang Z, Yang H, Wu Q, You L, Wang Y, Lin Y, et al. Chronic stress promotes colitis by disturbing the gut microbiota and triggering immune system response. Proc Natl Acad Sci U S A. 2018;115(13):E2960–9.

45. Lloyd Price J, Arce C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, Andrews E, Ajami NJ, Bonham KS, Brilawin JJ, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655–62.

46. Sarabrouzse G, Landolfi S, Olszak T, Neves JF, Avci FY, Enrik-Hademir D, Lu X, Zeissig S, Blumberg RS, Kasper DL. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell. 2014;156(1-2):123–33.

47. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14.

48. Van Zanten GC, Krych L, Royto H, Forssten S, Lahtinen SJ, Abu Al-Soud W, Sorensen S, Svensson B, Jepsen L, Jakobsen M. Symbiotic Lactobacillus acidophilus NCFM and cellbios does not affect human gut bacterial diversity but increases abundance of lactobacilli, bifidobacteria and branched-chain fatty acids: a randomized, double-blinded cross-over trial. FEMS Microbiol Ecol. 2014;90(1):225–36.

49. Pelck J, Martin A, Kolle P, Siebeck M, Strober W, Bovrindo M, Boirivin H, Rasmussen S, Svensson B, Jepsen L, Jakobsen M. Symbiotic Lactobacillus acidophilus NCFM and cellbios does not affect human gut bacterial diversity but increases abundance of lactobacilli, bifidobacteria and branched-chain fatty acids: a randomized, double-blinded cross-over trial. FEMS Microbiol Ecol. 2014;90(1):225–36.

50. Welcker K, Martin A, Kolle P,Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res. 2004;9(10):456–60.

51. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivin M, Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–14.

52. Marco ML, Heeney D, Binda S, Cifelli CJ, Cotter PD, Orligné B, Gänzle M, Kort RB, Flint HJ, Salminen S. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and